Intuitive Surgical (ISRG) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Intuitive Surgical (ISRG) has been on a powerful run, fueled by rising adoption of its da Vinci robotic systems and steady growth in surgical procedure volumes worldwide. The stock has outpaced both the S&P 500 and the broader medtech sector, underscoring investor confidence in its leadership within robotic-assisted surgery.
Both Intuitive Surgical and Boston Scientific posted strong Q3 results, but their sharply contrasting growth strategies make them very different investment stories.
Intuitive Surgical's Q3 results impress, with da Vinci 5 adoption driving 23% revenue growth, though sustaining this rapid momentum may pose new challenges ahead.
Intuitive Surgical (ISRG) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Fast-growing Intuitive Surgical just reported strong earnings, and the stock is rallying. Medtronic has a historically high yield, and its business is slowly getting back to growth.
Intuitive Surgical's stock has been on a tear since the medical pioneer exceeded Q3 expectations on Tuesday and provided positive guidance that left investors hyped about rising demand for robotic-assisted surgical systems.
Intuitive Surgical (ISRG) shares jumped Wednesday after the maker of robotic surgical devices posted much better-than-expected quarterly results and raised its guidance on increased use of its units.
Intuitive Surgical NASDAQ: ISRG is intuitively a good buy-and-hold stock because its industry-leading, in-demand products and services generate robust cash flow, driving consistent gains in shareholder value. The value is evident in its balance sheet and cash flow metrics, which enable it to buy back shares while investing in growth and maintaining one of the healthiest balance sheets on Wall Street.
The headline numbers for Intuitive Surgical (ISRG) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Intuitive Surgical stock (NASDAQ: ISRG) experienced an impressive 17% increase in extended trading on Tuesday, October 21, 2025, after significantly exceeding investor expectations with its Q3 results across all key metrics. The pioneer in medical robotics not only posted strong quarterly figures but also revised its full-year guidance upward, indicating ongoing momentum within the robotic surgery market.
Intuitive Surgical, Inc. (NASDAQ:ISRG ) Q3 2025 Earnings Call October 21, 2025 4:30 PM EDT Company Participants Dan Connally David Rosa - CEO & Director Jamie Samath - CFO, Head of Business Technology & Enterprise Technology Leader Conference Call Participants Robert Marcus - JPMorgan Chase & Co, Research Division Travis Steed - BofA Securities, Research Division Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Frederick Wise - Stifel, Nicolaus & Company, Incorporated, Research Division Patrick Wood - Morgan Stanley, Research Division David Roman - Goldman Sachs Group, Inc., Research Division Adam Maeder - Piper Sandler & Co., Research Division Presentation Operator Thank you for standing by, and welcome to the Intuitive Third Quarter 2025 Earnings Release. [Operator Instructions] As a reminder, today's program is being recorded.